Cuba develops a new antigen agaist Omicron variant
por An antigen against the Omicron variant of SARS-COV-2, developed by Cuban biopharmaceutical industry, is ready to be formulated into a vaccine candidate, and to start the corresponding preclinical and clinical trials, according to the Granma newspaper.